News | PET Imaging | June 14, 2016

Competition Seeks First PET Tracer for Key Parkinson's Protein

First team to develop viable tracer will receive $2 million prize from The Michael J. Fox Foundation

Michael J. Fox Foundation, MJFF, Parkinson's, PET tracer, competition, SNMMI 2016

June 14, 2016 — The Michael J. Fox Foundation (MJFF) announced a $2 million prize for development of a positron emission tomography (PET) tracer to visualize the protein alpha-synuclein, the priority therapeutic target and biomarker candidate of Parkinson's disease research. The prize aims to motivate the field toward this vital research tool, which would allow for earlier and more precise diagnosis, progression tracking, and more efficient and effective intervention testing.

"The ability to image alpha-synuclein in the brain would be a game-changer for Parkinson's translational research and would rapidly accelerate testing of therapies to slow or stop disease progression," said Jamie Eberling, Ph.D., MJFF director of research programs, who announced the prize at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting.

Academic and industry researchers, MJFF-funded or not, are eligible to apply for the prize. Contestants must provide pre-clinical and clinical data showing selectivity and viability of their alpha-synuclein radiotracer. Importantly, contestants must also agree to make their radiotracer available for use by the Foundation and MJFF awardees through a nonexclusive license or other MJFF-approved mechanism. There is no deadline for submission; the prize will go to the first team that shows compelling evidence.

Alpha-synuclein accumulates in the brains of people with Parkinson's disease, and researchers believe that aggregation is the cause of cell degeneration and death responsible for Parkinson's symptoms and progression. Five therapies that aim to prevent or degrade alpha-synuclein aggregates (called Lewy bodies) are currently in clinical trials, with more poised to enter human testing in the next few years.

However, the lack of an objective biological measure (or biomarker) of Parkinson's slows testing of new treatments. The ability to visualize alpha-synuclein in the brain would allow scientists to confirm diagnosis earlier, and thereby intervene earlier; monitor disease progression; and determine a patient's response to treatment in clinical studies.

MJFF is partnering Prothena Corp. plc, a biotechnology company developing protein immunotherapies for diseases including Parkinson’s, to support complementary work measuring alpha-synuclein in peripheral tissues and fluids.

The Michael J. Fox Foundation has long supported the pursuit of an alpha-synuclein PET tracer — in addition to funding of alpha-synuclein therapies and projects investigating peripheral measures of this key protein. In 2011, with little activity in the field, MJFF established a public-private Alpha-synuclein Imaging Consortium to begin work toward such a tool. If the Foundation consortium is the first to build compelling evidence of a viable, selective tracer, members of the team excluding MJFF staff will be awarded the prize. The Foundation also funds a number of independent studies toward an alpha-synuclein radiotracer.

For more information: www.michaeljfox.org

Related Content

Lightvision near-infrared fluorescence imaging system
News | Women's Health | September 11, 2018
Shimadzu Corp.
The Siemens Biograph Vision PET-CT system was released in mid-2018.

The Siemens Biograph Vision PET-CT system was released in mid-2018.

Feature | Nuclear Imaging | September 07, 2018 | By Dave Fornell
Nuclear imaging technology for both single photon emission computed tomography (SPECT) and positron emission tomography...
PET Imaging Agent Predicts Brain Tau Pathology, Alzheimer's Diagnosis
News | PET Imaging | September 05, 2018
Eli Lilly and Co. and Avid Radiopharmaceuticals Inc. announced a Phase 3 study of positron emission tomography (PET)...
Brain Iron Levels May Predict Multiple Sclerosis Disabilities
News | Neuro Imaging | August 31, 2018
A new, highly accurate magnetic resonance imaging (MRI) technique can monitor iron levels in the brains of multiple...
Study Finds Multiple Sclerosis Drug Slows Brain Shrinkage

An NIH-funded clinical trial suggested that the anti-inflammatory drug ibudilast may slow brain shrinkage caused by progressive MS. Image courtesy of Robert J. Fox, M.D., Cleveland Clinic.

News | Neuro Imaging | August 30, 2018
August 30, 2018 — Results from a clinical...
iSchemaView RAPID Technology Now Installed in More Than 500 Stroke Centers
News | Neuro Imaging | August 27, 2018
iSchemaView announced that more than 575 stroke centers in 22 countries have selected the RAPID advanced imaging...
Brain Study of 62,454 Scans Identifies Drives of Brain Aging
News | SPECT Imaging | August 27, 2018
In the largest known brain imaging study, scientists from five institutions evaluated 62,454 brain single photon...
Abnormal Protein Concentrations Found in Brains of Military Personnel With Suspected CTE

Researchers are using the tracer, which is injected into a patient, then seen with a PET scan, to see if it is possible to diagnose chronic traumatic encephalopathy in living patients. In this image, warmer colors indicate a higher concentration of the tracer, which binds to abnormal proteins in the brain. Credit UCLA Health.

News | PET Imaging | August 24, 2018
August 24, 2018 — In a small study of
Radiation Therapy Affects Event Recall for Children With Brain Tumors
News | Radiation Therapy | August 24, 2018
Children with certain types of brain tumors who undergo radiation treatment are less likely to recall the specifics of...
MRI Study Differentiates Brains of Doers from Procrastinators
News | Neuro Imaging | August 23, 2018
Researchers at Ruhr-Universität Bochum have analysed why certain people tend to put tasks off rather than tackling them...
Overlay Init